Detail akcie Lonza Group online

Business Summary: Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Lonza Group AG revenues increased 8% to SF6.72B. Net income before extraordinary items decreased 46% to SF654M. Revenues reflect Biologics segment increase of 14% to SF3.72B, Small Molecules segment increase of 10% to SF901M, Japan segment increase from SF227M to SF544M, Switzerland segment increase of 17% to SF1.17B.